9-ing-41

Phase 2

GGlenn J. Hanna

9-ing-41 is one of 16 therapeutic programs targeting Salivary Gland Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Salivary Gland CancerActive, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Salivary Gland Cancer

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Approved

—2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Keytruda

3 4

Alimta

EEagle Pharmaceuticals, Inc.

Phase 2

1 5

Navmi

SSummit Therapeutics

Phase 2

1 6

Paraplatin

AAvyxa

Phase 2

1 7

Pucotenlimab

SSun Yat-sen University

Phase 2

1 8

Xpovio

KKaryopharm Therapeutics Inc

Preclinical

1 9

Casodex

IIstituto Clinico Humanitas

Preclinical

1 10

Leuprorelin

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pancreatic Adenocarcinoma

NCT05077800

Q2 2027

Phase 2Active, not recruiting

Salivary Gland Cancer

NCT05010629

Clinical

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting·CColin D. Weekes, M.D., PhD·Phase 2·NCT05077800·70 enrolled

Salivary Gland Cancer1 trial

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Active, not recruiting·GGlenn J. Hanna·Phase 2·NCT05010629·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for 9-ing-41. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 9-ing-41. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Glenn J. Hanna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: GGlenn J. Hanna

9-ing-41

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

Salivary Gland Cancer1 trial

References

Drug Info

Quick Facts

Related News